Use of the XRCC2 promoter for in vivo cancer diagnosis and therapy

The homologous recombination (HR) pathway is a promising target for cancer therapy as it is frequently upregulated in tumors. One such strategy is to target tumors with cancer-specific, hyperactive promoters of HR genes including RAD51 and RAD51C. However, the promoter size and the delivery method h...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu, Li, Zhen, Xu, Zhu, Tang, Huanyin, Guo, Wenxuan, Sun, Xiaoxiang, Zhang, Wenjun, Zhang, Jian, Wan, Xiaoping, Jiang, Ying, Mao, Zhiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856804/
https://www.ncbi.nlm.nih.gov/pubmed/29549248
http://dx.doi.org/10.1038/s41419-018-0453-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856804/
https://www.ncbi.nlm.nih.gov/pubmed/29549248
http://dx.doi.org/10.1038/s41419-018-0453-9

Ejemplares similares